Frank Diamond

Health plans need ironclad cases against doctors they exclude from their networks or it could cost them. A jury in Los Angeles last month awarded $3.8 million in compensatory damages to Jeffrey Nordella, MD, a primary care physician whose application to join the Anthem Blue Cross provider network was denied in 2010.

California’s superior court agrees with Nordella that he was turned away because he had been a strong advocate for patients over the years. In denying Nordella’s request, Anthem nullified Nordella’s right to “fair procedure” and did so with malice, oppression, and fraud, a jury found.

Health plans get in trouble if they don’t follow their own procedures, or if the reason they claim for their action is not documented in the record, or if they are simply wrong on the facts, says Alice Gosfield.

Anthem spokesman Darrel Ng says, “Dr. Nordella and Anthem Blue Cross have agreed to confidentially resolve any and all disputes between them.” That agreement — reached after the verdict on the compensatory damages and before a scheduled hearing on the punitive damages — covers all claims and it is safe to assume, according to a source close to the case, that Nordella has gotten at least the $3.8 million.

Perhaps the most surprising aspect of this case is that it even got to a jury, according to Alice G. Gosfield, a health care lawyer and member of the Managed Care Editorial Advisory Board. Most never reach trial, and certainly don’t result in such large settlements.

Surprising aspect

Gosfield cites a Los Angeles Times article ( in noting that Anthem claimed to have 137 primary care physicians in its network who worked within 10 miles of Nordella in Porter Ranch, Calif., but could name only seven. That kind of lapse might have bolstered Nordella’s argument that Anthem was not acting in the best interests of its members by excluding PCPs in an era where there’s a growing shortage and need for such providers.

Anthem also lost points because at the time Nordella was denied entry into the insurer’s provider network, he’d also been the medical director of Porter Ranch Quality Care, an urgent care unit. “Anthem had said it needed more urgent care physicians in that area, while they were turning him away,” says Gosfield.

Gosfield says that health plans get in trouble if they don’t follow their own procedures, or if the reason they claim for their action is not documented in the record, or if they are simply wrong on the facts.

Theresa Barta, Nordella’s lawyer, agrees with Gosfield and tells Managed Care that insurers and health plans “should have well defined guidelines that govern their decisions regarding admitting and denying physicians into their provider networks, and most importantly, those guidelines should be made available to applying physicians and followed without exception.”

Gosfield warns that “we might see more cases go further on these issues as we see more narrow networks. Unless the plans tighten up their acts in terms of having clear standards, applying them uniformly and documenting their decision making effectively, they will be vulnerable to these kinds of actions.”

Managed Care’s Top Ten Articles of 2016

There’s a lot more going on in health care than mergers (Aetna-Humana, Anthem-Cigna) creating huge players. Hundreds of insurers operate in 50 different states. Self-insured employers, ACA public exchanges, Medicare Advantage, and Medicaid managed care plans crowd an increasingly complex market.

Major health care players are determined to make health information exchanges (HIEs) work. The push toward value-based payment alone almost guarantees that HIEs will be tweaked, poked, prodded, and overhauled until they deliver on their promise. The goal: straight talk from and among tech systems.

They bring a different mindset. They’re willing to work in teams and focus on the sort of evidence-based medicine that can guide health care’s transformation into a system based on value. One question: How well will this new generation of data-driven MDs deal with patients?

The surge of new MS treatments have been for the relapsing-remitting form of the disease. There’s hope for sufferers of a different form of MS. By homing in on CD20-positive B cells, ocrelizumab is able to knock them out and other aberrant B cells circulating in the bloodstream.

A flood of tests have insurers ramping up prior authorization and utilization review. Information overload is a problem. As doctors struggle to keep up, health plans need to get ahead of the development of the technology in order to successfully manage genetic testing appropriately.

Having the data is one thing. Knowing how to use it is another. Applying its computational power to the data, a company called RowdMap puts providers into high-, medium-, and low-value buckets compared with peers in their markets, using specific benchmarks to show why outliers differ from the norm.
Competition among manufacturers, industry consolidation, and capitalization on me-too drugs are cranking up generic and branded drug prices. This increase has compelled PBMs, health plan sponsors, and retail pharmacies to find novel ways to turn a profit, often at the expense of the consumer.
The development of recombinant DNA and other technologies has added a new dimension to care. These medications have revolutionized the treatment of rheumatoid arthritis and many of the other 80 or so autoimmune diseases. But they can be budget busters and have a tricky side effect profile.

Shelley Slade
Vogel, Slade & Goldstein

Hub programs have emerged as a profitable new line of business in the sales and distribution side of the pharmaceutical industry that has got more than its fair share of wheeling and dealing. But they spell trouble if they spark collusion, threaten patients, or waste federal dollars.

More companies are self-insuring—and it’s not just large employers that are striking out on their own. The percentage of employers who fully self-insure increased by 44% in 1999 to 63% in 2015. Self-insurance may give employers more control over benefit packages, and stop-loss protects them against uncapped liability.